Get started
Author

Tracy Summa

Observed names: T Summa, T. Summa
ORCID: 0000-0002-9275-8649
Observed ORCID: 0000-0002-9275-8649
OpenAlex ID: A5035564559
Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2023 · Andrew A. Davis, Jingqin Luo, et al. · Clinical Cancer Research · 48
PDF
A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN)
2023 · Foluso O. Ademuyiwa, Donald W. Northfelt, et al. · npj Breast Cancer · 22
PDF
A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis
2022 · Jairam Krishnamurthy, Jingqin Luo, et al. · npj Breast Cancer · 22
PDF
Abstract P1-19-13: A phase II trial assessing the safety of an alternative dosing schedule of palbociclib (palbo) in hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC): Alt Dose Palbo
2020 · Jairam Krishnamurthy, Jingqin Luo, et al. · Cancer Research · 4
Abstract P2-13-01: Phase 2 study of neoadjuvant palbociclib, letrozole, and trastuzumab in patients with ER+ HER2+ breast cancer (PALTAN)
2022 · Foluso O Ademuyiwa, Donald Northfelt, et al. · Cancer Research · 3
Supplementary Table 2 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2025 · Andrew A. Davis, Jingqin Luo, et al.
PDF
Supplementary Figures S1-S15 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2025 · Andrew A. Davis, Jingqin Luo, et al.
PDF
Supplementary Methods S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2025 · Andrew A. Davis, Jingqin Luo, et al.
PDF
Supplementary Table 1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2025 · Andrew A. Davis, Jingqin Luo, et al.
PDF
Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2025 · Andrew A. Davis, Jingqin Luo, et al.
Supplementary Table 3 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2025 · Andrew A. Davis, Jingqin Luo, et al.
PDF
Abstract P3-12-21: NeoTAILOR: A phase II biomarker-directed approach to guide neoadjuvant therapy for patients with clinical stage II/III ER+, HER2- negative breast cancer
2025 · Nusayba Bagegni, Tracy Summa, et al. · Clinical Cancer Research
Supplementary Table 3 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2024 · Andrew A. Davis, Jingqin Luo, et al.
PDF
Supplementary Figures S1-S15 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2024 · Andrew A. Davis, Jingqin Luo, et al.
Supplementary Table 1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2024 · Andrew A. Davis, Jingqin Luo, et al.
PDF
Supplementary Methods S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2024 · Andrew A. Davis, Jingqin Luo, et al.
PDF
Supplementary Table 3 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2024 · Andrew A. Davis, Jingqin Luo, et al.
Supplementary Table 1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2024 · Andrew A. Davis, Jingqin Luo, et al.
Supplementary Figures S1-S15 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2024 · Andrew A. Davis, Jingqin Luo, et al.
PDF
Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2024 · Andrew A. Davis, Jingqin Luo, et al.
Supplementary Methods S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2024 · Andrew A. Davis, Jingqin Luo, et al.
Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2024 · Andrew A. Davis, Jingqin Luo, et al.
Supplementary Table 2 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2024 · Andrew A. Davis, Jingqin Luo, et al.
PDF
Supplementary Table 2 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2024 · Andrew A. Davis, Jingqin Luo, et al.
Supplementary Figures S1-S15 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
2023 · Andrew A. Davis, Jingqin Luo, et al.
PDF
Works count: 58
Citation count: 99
H-index: 4
I10-index: 3
Year
Topic
Type